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Abstract
In addition to the association between overweight/obesity and cardiovascular disorders, with the presence of a vascular
burden as a cofactor, recent studies have particularly focused on the association between indicators of adiposity and dementia.
Particularly, renewed predictive value has been addressed to body mass index (BMI). A high BMI can increase the risk
for dementia when measured before clinical dementia onset. Although the use of BMI in population-based and clinical
studies is feasible, this is an index of weight excess and shows limits in its ability to distinguish between fat and fat-free
mass or between deep (visceral) abdominal fat and subcutaneous abdominal fat. In this scenario, we suggest that visceral
adipose tissue (VAT) rather than BMI should be considered as a concurrent factor in the development of dementia. Several
physiopathologic theories (neurochemical, hormonal, atherosclerotic and inflammatory) have been proposed to explain the
decline of cognitive functions. Along with this, well known cardiovascular risk factors (dyslipidaernia, insulin resistance,
blood pressure, adipocytokine/chemokines, atherosclerosis) contributing to the development of cognitive decline seemmore
strongly related to body fat distribution, particularly visceral adipose tissue (VAT), rather than to BMI. With this regard, VAT
may be reasonably considered to play a predominant role.
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Introduction
Dementia is a clinical state of severe cognitive impairment
that likely reflects the summed effects of multiple
pathological processes associated with advanced ageing.
Recently, particular attentionhas focussedon the presence
of a longitudinal link between middle-age adiposity [1, 2]
and later-life obesity [3, 4] and the decline in cognitive
function. Thus, obesity seems responsible for further health
implications besides cardiovascular disorders (CVD), and
the presence of a vascular burden is nowadays recognised
as a possible common cofactor in the development of
dementia [2]. The recent systematic review by Gorospe and
Dave [1] supports the hypothesis that an increased bodymass
index (BMI) is independently associated with an increased
risk of dementia. Though, as the authors themselves have
pointed out, the mechanisms underlying this relationship are
still unclear [1].
Recent preliminary studies suggest that the role of abdom-
inal obesity should deserve further investigation [2–4].
In this commentary, we wish to point out the advantages
and disadvantages of BMI compared to visceral adipose
tissue (VAT) and to emphasise that VAT rather than BMI
may be the risk factor for dementia.
Although BMI is widely accepted as a simple marker
of adiposity in population-based studies, and is recognised
as an instrument to diagnose obesity for all age-groups
(BMI ≥30 kg/m2), it should be more properly seen as
an index of weight excess, rather than body fatness. The
disadvantage of BMI measurement is that it does not
provide information on body composition or distinguish
between fat and fat-free mass or between deep (visceral)
abdominal fat and subcutaneous abdominal fat. Along with
this neurochemical, hormonal, inflammatory molecules and
vascular factors implicated in cognitive decline are related
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Visceral adipose tissue and cognitive decline
to adipose tissue distribution (and in particular VAT) rather
than to general measures of overweight/adiposity (BMI).
An example of how VAT, instead of BMI, is involved
in the determination of cognitive decline is provided by
the analysis of specific vascular (atherosclerosis and blood
pressure) and metabolic risk factors (insulin resistance and
hyperglycaemia).
Atherosclerosis is considered among the possible factors
involved in the development of both vascular dementia and
Alzheimer’s disease (AD) and a physiopathological model
based on multiple asymptomatic brain injuries related to
peripheral vascular disease has been proposed [5].
Regardless of BMI, patients with increased intra-
abdominal fat usually have an atherogenic lipid profile,
high fasting serum glucose and insulin levels and high
blood pressure, all metabolic factors participating in the
atherosclerotic process. These factors in turn contribute to
the occurrence of coronary heart disease, stroke, as well as
peripheral vascular diseases [6–8].
Several studies report that blood pressure, decades before
the onset of the cognitive decline, can play a role in the
determination of dementia but the exact underlying mecha-
nisms are not fully explained [2, 5, 9, 10]. Some studies have
demonstrated that a higher systolic blood pressure is asso-
ciated with an increased risk for Alzheimer’s disease and
vascular dementia in the elderly, probably due to artery stiff-
ness and severe atherosclerosis [9]. Hypertension is also a risk
factor for stroke and contributes to the development of white
matter hypertensive lesions on brainMRI studies.Other anal-
yses have shown an inverse association with low diastolic
levels, particularly in patients taking antihypertensivemedica-
tions, and in whom poor cerebral perfusion has been singled
out as the responsible factor [10]. It is worth noting that
VAT has been indicated as the most important contributor
to hypertension, and indices of abdominal fat deposition have
been demonstrated asmore significantly related to high blood
pressure than BMI [7]. In addition, hypertension is a risk fac-
tor frequently associated with insulin resistance (IR) [7, 8].
Diabetes, metabolic syndrome and more widely IR
have been included among the strongest factors involved
in the association between the decline of cognitive
function and BMI [2, 11, 12]. The metabolic syndrome is
a cluster of factors (abdominal obesity–described by waist
circumference–hypertriglyceridaemia, low- and high-density
lipoprotein level, hypertension and fasting hyperglycaemia)
and a commonly accepted precursor to diabetes. Both
these conditions have been demonstrated as significantly
associated to vascular disease [7, 8, 13]. With regard to the
implications of visceral adiposity in health and disease, recent
investigations show that intra-abdominal fat accumulation,
rather than BMI, is a significant independent predictor
of the IR, impaired glucose tolerance and dyslipidaemia
seen in both metabolic syndrome and diabetes [6, 7]. There
is general agreement that VAT affects IR and glucose
metabolism through a higher rate of basal lipolysis and
free fatty acids (FFAs) overflow to the liver [14]. However,
the excess of systemic FFA availability is related to overall
upper-body fat (visceral and non-visceral) [14]. Although
no direct link has been demonstrated so far between
FFAs and cognitive decline in humans, in vitro studies
suggest that an increased availability of FFAs is associated
with more pronounced molecular and histopathological
degeneration of neurons [15]. Also, hyperinsulinaemia is
a frequent correlate of expanded VAT [6, 7]. Accordingly,
the direct action of insulin on brain structures has been
considered among the possible physiopatholgical factors
involved in the development of dementia [2, 3]. Furthermore,
IR represents a model of systemic chronic low-grade
inflammatory background [7, 16].
An atherosclerotic model of systemic inflammation,
similar to the one suggested for CVD, was also proposed
to explain the higher cognitive impairment in these subjects
having higher plasma levels of inflammatory markers (e.g.
C-reactive protein, interleukin 6) [2, 11, 17].
Nowadays, adipose tissue should be considered as the
largest endocrine organ, and it is well known that the intra-
abdominal compartment is metabolically more active as a
source of cytokines, chemokines and hormone-like proteins,
such as tumour necrosis factor-alpha (TNF-α), interleukin
6 (IL-6), monocyte chemoattractant protein 1 (MCP-1) and
the newly isolated protein, visfatin [16].
Quantitativemeasurements of the abdominal fat depot, in
uncomplicated obesity, appear to account far more than BMI
(strong correlation) for the circulating levels of several of
thesemolecules (C-reactive protein,MCP-1, IL-6, soluble IL-
6 receptor, TNF-α and soluble TNF receptor-I) and indicate
VAT as the main contributor [18, 19]. This hypothesis is
confirmed by several genetic studies showing higher mRNA
expression and protein release of these mediators [16]. Most
of them exert an action of inflammatory pathway activators
both at the site of fat distribution (paracrine action) and also
systemically (endocrine action) [16]. This contributes to the
possible relationship between VAT and an increase of CVD
risk [6, 16, 18, 19]. Thus, the role of both central obesity and
the systemic action of VAT products has been proposed
as factors affecting brain health and subsequent cognitive
decline.
Conclusions and Perspectives
BMI, as a readily available measure of weight excess,
seems to be a good predictor of both vascular dementia
and AD [1, 2, 5, 9, 20], but this measure is limited by
the lack of information on body composition and
the distribution of body fat. Moreover, factors known
to be involved in the development of both vascular
dementia and AD such as, hypertension, insulin resistance,
pro-inflammatory molecules (adipocytokine-cytokine), and
atherosclerosis seem more strongly related to body fat
distribution, particularly VAT, rather than to BMI. However,
VAT quantification implies imaging techniques and does
not fit in a clinical setting as easily as BMI. There
are, however, anthropometric surrogates, such as waist
circumference (WC), waist-to-hip and waist-to-height ratios
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(WHR and WHtR, respectively) which are readily available
and are routinely used by nutritionists, diabetologists,
endocrinologists and cardiologists. Although limitations due
to poor reproducibility (e.g. variability in landmarks) have
been pointed out, the routine measurement of waist and
hip circumference and height is feasible and the use of
anthropometric indicators would be also conceivable in a
neurological setting.
Future prospective studies may confirm whether VAT
and its surrogate measures (WC, WHR, WHtR) actually
are a risk factor for cognitive decline. Probably, focusing
attention on the pathologic distribution of adipose tissue,
rather than on the presence of overt obesity alone, may
provide an additional evidence for VAT implications in
an inflammatory-atherosclerotic model of cognitive decline.
In this respect, it will be also interesting to compare
whether the pathological distribution of adipose tissue most
strongly correlates with AD compared to vascular dementia,
considering the different contributions of small vessel disease
to the former compared to the latter, in which genetic risk
should be considered.
In any case, the relationship between BMI and dementia
does not seem to be a simple one. Some authors have shown
that it is most likely a J-shaped curve, where a low BMI
represents a strong risk factor [4, 20]. In some cases, this
association may be the result of weight loss, which might
have masked the detrimental effects of increased visceral
adiposity in middle age [4, 21]. In others, no certain cause
has been demonstrated so far, although hyperinsulinaemia
has been singled out as a possible contributor [4]. Thus, when
addressing underweight people, the use of anthropometric
surrogates alone is an obvious limitation, while that of BMI
as well as of body weight history still conserves a great value.
For decades, BMI has been used as a simple indicator of
nutritional status in most countries. Thus, it will take a long
time before anthropometric data becomes available in the
routine clinical setting.
Key points
• Growing evidence supports the idea that an increased
body mass index (BMI) is a risk factor for dementia.
However, the mechanisms underlying this relationship
still need to be explained.
• Several physiopathological theories (neurochemical,
hormonal, atherosclerotic and inflammatory) have
been proposed to explain the decline of cognitive
functions.
• Interestingly, many of the vascular (hypertension,
atherosclerosis), inflammatory (adipocytokine-cytokine)
and metabolic factors (insulin resistance, fasting hyper-
glycaemia) contributing to the development of cognitive
decline seem more strongly related to body fat distribu-
tion, particularly the visceral adipose tissue (VAT), rather
than to BMI.
• In this regard, we suggest that VAT instead of BMI might
therefore be considered as a risk factor for cognitive
decline.
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